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Abstract

7

Objective: To review the evidence for the role of dietary modifications in alleviating chronic fatigue

8

syndrome symptoms.

9

Methods: A systematic literature review was guided by PRISMA and conducted using Scopus,

10

CINAHL Plus, Web of Science and PsycINFO scientific databases (1994-2016) to identify relevant

11

studies. Twenty-two studies met the inclusion criteria, the quality of each paper was assessed and

12

data extracted into a standardised tabular format.

13

Results: Positive outcomes were highlighted in some included studies for polyphenol intakes in

14

animal studies, D-ribose supplementation in humans and aspects of symptom alleviation for one of

15

three polynutrient supplement studies. Omega three fatty acid blood levels and supplementation

16

with an omega three fatty acid supplement also displayed positive outcomes in relation to chronic

17

fatigue syndrome symptom alleviation.

18

Conclusions: Limited dietary modifications were found useful in alleviating chronic fatigue

19

syndrome symptoms, with overall evidence narrow and inconsistent across studies.

20

Implications for Public Health: Due to the individual and community impairment chronic fatigue

21

syndrome imparts on the population, it is vital that awareness and further focused research on this

22

topic is undertaken to clarify and consolidate recommendations and ensure accurate, useful

23

distribution of information at a population level.

24
25

Abstract Word Count: 193

26
27

Introduction

28

Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME), recently redefined by the

29

Institute of Medicine as Systemic Exertion Intolerance Disease (SEID)1, is a chronic multisystemic

30

condition which severely impacts daily life, impairing a persons ability to perform every day tasks

31

due to overwhelming fatigue, in turn affecting quality of life.1-6 For the purpose of this review the

32

term CFS will be used. Symptoms characteristic to CFS include immobilising fatigue, sleep

33

disturbance, headaches, difficulty concentrating as well as muscular pain.2, 5 The aetiology behind

34

CFS is unknown, with new diagnostic criteria1 and name (SEID) aimed at improving diagnostic

35

time as well as consolidating the focus of new research to address the cause of CFS.1, 3, 4, 6

36

Furthermore, recent findings of an objective characteristic chemical signature for CFS are hoping to

2

37

also prove useful in eliminating diagnostic uncertainty going forward, highlighting CFS as a pattern

38

of hypometabolic response to environmental stress.7 CFS community prevalence is estimated to be

39

0.2% to 0.7% in the United States and United Kingdom,6, 8, 9 although valid epidemiological data is

40

limited.3, 10, 11 Not only is the individual and their quality of life impacted but the community itself

41

is as well. The economic impact of CFS within the limited Australian data available is estimated at

42

$13471 annually per case for the year 2000 for individual medical costs and time lost in

43

productivity.8 The overall annual direct and indirect economic costs being estimated at $525

44

million.8 More recent United States data suggests an annual direct and indirect cost estimate of $17-

45

24 billion dollars.12 Research into effective treatment of CFS symptoms is vital, particularly that

46

addressing treatment using dietary modification rather than pharmacological measures.

47

Previous reviews on CFS have not concentrated solely on the effectiveness of dietary modification,

48

as, to the knowledge of the authors, data specific to this research question is limited.5, 13-15

49

Complementary and alternative medicine therapies were the focus of previously conducted CFS

50

reviews, with some studies briefly discussing dietary modification amongst a vast range of other

51

alternative and pharmacological therapies.5, 13-15 This review intends to highlight research in this

52

field with specific focus on dietary modifications alone. By examining the current literature

53

surrounding the topic, this review will identify effective dietary modifications for use. Due to the

54

narrow extent of studies available,5, 13-15 literature reviewed in this study is comprised of data on

55

dietary modification by food, supplementation or dietary outcome assessment and its impact on

56

alleviating the symptoms of persons with CFS across a range of study designs. Inclusion across a

57

range of study designs effectively highlights the current state of evidence for this topic. This study

58

aims to review data on dietary modification in food or supplement form or dietary outcome

59

assessment in relation to CFS. The research hypothesis stands on the alternative hypothesis that

60

dietary modifications alone are useful in alleviating the symptoms of CFS.

61
62

Methods:

63

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement

64

protocol was used to inform the methods used in this systematic review16 (Supplementary File 1).

65

Data Collection

66

The scientific databases Scopus, CINAHL Plus, Web of Science and PsychINFO were searched in

67

May 2014 (1994-2014). A date limit was applied due to limited awareness and work surrounding

68

CFS, with the first case definition only developed after 1988.10 An updated database search was

69

performed for the period of June 2014 to August 2016, limited only by date. The search terms,

70

developed from the initially selected key words, medical subject headings (MeSH) terms and

71

synonyms, were used within Boolean search strategies across the for-mentioned databases. The
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72

search terms included “chronic fatigue syndrome”, “CFS”, “myalgic encephalomyelitis”, “diet” and

73

“supplementation”.

74

To systematically gather all available evidence, animal as well as human observational and

75

experimental study designs were included if they met inclusion criteria parameters. The broad range

76

of study designs were chosen to be included as the extent of research surrounding this topic is

77

narrow.

78
79

Study Selection

80

For inclusion in this review, studies needed to provide data on dietary outcomes assessment or

81

modification in food or supplement form in relation to CFS and its symptoms, or a model of CFS

82

and its accompanying symptoms. For those studies considering supplement use, the Therapeutic

83

Goods Regulations 199017 was consulted, with a number of designated active ingredients excluded

84

from inclusion in this review. This ensured the review held its focus on dietary modification rather

85

than pharmacological measures. Studies were required to be published studies in the English

86

language, and were excluded if published more than twenty two years ago. Only original studies

87

were included with editorials and letters excluded. Studies were selected ensuring that they met the

88

inclusion criteria, had relevant findings and showed some level of validity through quality

89

assessment methods.18-20

90

Relevant studies were selected from the pool of studies returned by the searches performed across

91

each database by initially screening the title and abstract. For preliminary screening, if the title and

92

abstract did not provide sufficient information or the abstract was unavailable the full study was

93

screened. The subsequent full text studies were then reviewed to ensure they met the inclusion

94

criteria, were primary studies and were not reviewing disproved treatment strategies such as

95

homeopathy.21

96
97

Data Extraction

98

Upon gathering data from the included primary studies, a standardised table was developed in order

99

to extract appropriate information (see Supplementary File 2, accessible online). The data extracted

100

from each study pertained to study design, level of evidence18 and use of a control group. It also

101

included the intervention details (range of exposure and length to follow up), study population

102

characteristic (sample size, gender, loss to follow up or non-response), duration, outcome measures,

103

results, confounders, external validity (applicability and generalisablity) as well as an overall

104

quality rating20 which was reached through in depth assessment of study validity.

105
106

Quality and Risk of Bias Assessment
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107

For the included primary studies the level of evidence of each included study was graded according

108

to the National Health and Medical Research Council18 A quality rating was assigned according to

109

the Academy of Nutrition and Dietetics American Dietetic Association20 quality rating checklist,

110

allowing for an assessment of risk of bias within each included study and fostering systematic and

111

objective quality rating assignment. The checklist addresses relevance, applicability, validity and

112

bias,20 These aspects of quality and bias are found within the summary table. Ethics approval of all

113

included studies was also considered.

114
115

Study Outcomes

116

The summary table was used to systematically extract data from each study included in the review

117

in order to make clear comparisons and provide a brief overview of all studies. Results are reported

118

according to prominent data themes which emerged from the review.

119
120

Results

121

Study Retrieval

122

Across the identified databases 435 potential primary research papers were identified (see

123

Supplementary File 3 for expanded search details, viewable online). Of these, 22 primary research

124

papers were included in the systematic review.

125
126

Animal studies and polyphenols

127

Three animal studies were included examining the effect of differing polyphenols and their impact

128

on induced CFS symptoms in mice or rats.22-24 These polyphenols included astragalus

129

membranaceus flavonoids (AMF), epigallocatechin gallate (EGCG) and naringin.

130

The effect of AMF oral administration in rats highlighted statistically significant increases in

131

endurance through forced swimming compared to rats not administered with AMF (p<0.05) in the

132

chronically fatigued groups.22 Spleen cell proliferation was statistically significantly increased with

133

AMF supplementation (p<0.05) as well as abnormal cytokine production levels being regulated

134

(p<0.05) in chronically fatigued groups.22

135

Daily EGCG oral administration highlighted a significant increase in endurance capacity during

136

forced swimming and decreased post swim fatigue levels compared to the chronic fatigue rat group

137

at 28 days (p= <0.05). Greater endurance and decreased post fatigue levels were displayed with the

138

administration of 100 mg/kg compared to 50 mg/kg (p<0.05).23 Use of EGCG prevented reductions

139

in body weight and restored spleen and thymus induced hypotrophy compared to the chronic fatigue

140

rat group (p<0.05), with significantly greater prevention of body weight reduction and spleen

141

hypertrophy restoration using 100mg/kg dose verse 50mg/kg dose (p<0.05).23 In an elevated plus

142

maze learning task administration of EGCG decreased initial transfer latency compared to the
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143

chronic fatigued group (p= <0.05). Use of an oral dose of EGCG also showed favourable

144

statistically significant changes in measures of oxidative and nitrosative stress and pro-

145

inflammatory cytokine levels, factors which may contribute to fatigue development.22-24

146

For the polyphenol naringin, differing oral doses were administered to mice treated with

147

lipopolysaccharide (LPS) or brucella abortus (BA) antigen which induced immunological fatigue.24

148

Naringin use showed a statistically significant and dose-dependent decrease in the duration of

149

immobility in immunologically induced fatigued mice (p= <0.05) and a significant increase in mean

150

tail withdrawal latency compared to BA or LPS injected mice (p= <0.05).24 A statistically

151

significant dose dependant increase in reduced glutathione levels was also seen through naringin

152

administration compared to BA or LPS injected mice (p= <0.05).24 Again, as seen with use of the

153

other polyphenols, statistically significant favourable changes in measures of oxidative and

154

nitrosative stress and a pro-inflammatory cytokine were highlighted.24

23

155
156

Dietary interventions and CFS symptom alleviation

157

Only one eligible study assessed a dietary intervention with reference to CFS symptoms

158

alleviation.4 The experiment applied a twenty-four week intervention of a low sugar low yeast diet

159

(LSLY), with intention to treat analysis showing no statistically significant difference for the

160

intervention and guideline based healthy eating control between the primary outcome measures.4

161

Compliance was poor, compliant analysis was performed only on baseline characteristics

162

comparing those who completed their role in the experiment and those that did not.4

163
164

Dietary intake and poor vitamin or mineral status and CFS

165

Three studies examined dietary intake and associated correlations to CFS.25-28 Differing dietary

166

intake patterns were highlighted through a descriptive observational study design, with findings of

167

dairy and grain avoidance most prominent in the CFS cohort evaluated.25 These dietary restrictions

168

in many cases were reported to be undertaken due to provision of non-evidence based information

169

and diagnostic testing from alternative therapy practitioners.25 Very little correlation of abnormal

170

biomarkers with inadequate nutritional intake in CFS patients was displayed in another descriptive

171

observational study.28 The findings continued in a consistent manner highlighting through an

172

analytical observational study 95% had poor fibre intake and 70% had unhealthy fat, fruit, and

173

vegetable intake measured through defined cut off limits from questionnaire assessment tools.27

174

Yet, lifestyle factors including overweight and unhealthy dietary intake were not significantly

175

associated with fatigue severity or functional impairment.27

176

One study considered the vitamin status and direct association of CFS symptoms alleviation. The

177

analytical observational study examined mean serum 25 OH vitamin D levels. Levels were

178

highlighted to be moderately to severely suboptimal in CFS participants at 60.1% for those not
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179

taking supplements. This finding was statistically significantly lower over winter/spring (p= <0.04)

180

and summer/autumn (p= <0.003) compared to the general population control study arm,26 yet no

181

observed relationship for alleviation of symptoms of CFS was seen.26

182
183

Supplements and CFS symptom alleviation

184

Three experimental studies examined use of single nutrient supplements.33-35 Following on from the

185

aforementioned serum 25 OH vitamin D analysis, an experimental trial investigated the use of an

186

oral vitamin D3 supplement.35 The measured outcomes from this trial pertinent to the review

187

highlighted no statistically significant improvement for both fatigue or for the selected markers of

188

inflammatory and oxidative stress.35

189

Secondly, probiotic supplementation was examined finding no significant change.33 Six of fifteen

190

participants in this study did report subjective improvement after the trial and statistically

191

significant improvement was seen for the neurocognitive function measures (p= 0.04), yet no

192

significant changes in aerobic intestinal microflora were found.33

193

Another study observed supplementation using D-ribose.34 Significant improvement for energy

194

levels between pre and post enrolment in the compliant analysis was seen (p<0.0001, CI; 1.1-2.2)

195

and 65.7% of participants indicated improvement in regard to their overall subjective feelings.34

196

Regarding the experimental studies examining polynutrient supplements, one vitamin and mineral

197

supplement study highlighted statistically significant improvements for before and after

198

measurements of superoxide dismutase (SOD) antioxidant enzyme activity (p≤ 0.005).31 Aspects of

199

fatigue measures showed statistically significant improvement in fatigue itself (p= 0.0009), sleep

200

disorder (p= 0.008), autonomic nervous system symptoms (p= 0.018), headaches (p= 0.0001), and

201

subjective feelings surrounding infection (p= 0.0002).31 Some aspects of quality of life measures

202

were also statistically significant including total physical function (p= 0.053), physical role (p=

203

0.031), pain (p= 0.01), mental vitality (p= 0.029) and mental health function scores (p= 0.014).31

204

Yet, in another study trialing a vitamin and mineral supplement no statistically significant

205

relationship was seen.32 Furthermore, another study also experimentally addressed polynutrient

206

supplementation seeing no statistically significant results with fatigue, disability and symptoms

207

assessed through the primary measured outcomes.30

208

Lastly, practices of mixed self-applied supplementation were observed in an analytical

209

observational study.29 Minimal changes in fatigue were shown over the follow up period in

210

response to a range of different self-applied therapies, including nutritional therapies.29 A small

211

number of the total cohort found a nutritional therapy useful, with ginseng found to be most helpful

212

(56%) within users.29 Measured outcomes compared to effect of different nutritional therapies

213

revealing inconsistent results. Magnesium (no specified dose) at six months was statistically

214

significant with improvement in fatigue (p= 0.002), yet at two years showed no significant
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215

relationship. Calcium (no specified dose) was introduced by participants at six months to two

216

years and showed statistically significant improvement in fatigue (p= 0.01), yet was based on five

217

participants.29

29

218
219

Fatty acids and CFS symptom alleviation

220

Three eligible studies regarding fatty acids were considered in relation to CFS symptoms.36-38 In an

221

analytical observational study a statistically significant reduction was shown in the CFS cohort for

222

the omega three (n-3) to omega six (n-6) polyunsaturated fatty acid (PUFA) ratio (p= 0.0003) and

223

eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (p= 0.02).36 A statistically significant

224

positive relationship was also observed between n-3 to n-6 PUFA ratio and serum zinc (p= 0.009),

225

an indicator of the inflammatory response.36 A statistically significant relationship between lowered

226

n-3 PUFA and the expression of CD69 on activated T cells (p= <0.05) was seen.36 There was also a

227

statistically significant positive relationship between the severity of CFS symptoms and certain n-

228

6,PUFA, n-9 PUFA, oleic and palmitic acid (p= <0.05) and a statistically significant negative

229

relationship between n-3 to n-6 ratio and severity of CFS symptoms (p= 0.027).36

230

An essential fatty acid (EFA) supplement rich in EPA was individually examined in a case study.37

231

Depression scores dropped from 27 at baseline to 3 at 16 weeks and the lateral ventricular volume

232

of the brain had decreased at 16 weeks for the CFS participant.37 Yet, another experimental trial of

233

an EFA supplement verse a placebo supplement of sunflower oil showed no statistically significant

234

difference in the RBC membrane fatty acid profile and symptoms scores between the intervention

235

and control group.38

236
237

Tryptophan and glutamine amino acids and CFS

238

The amino acid tryptophan (Trp) and its potential role in CFS symptoms expression was examined

239

in two studies.39, 40 Within one, the selected CFS cohort displayed a significantly higher mean free

240

(48%, p= 0.0000) and total Trp (19%, p= 0.0016).39 Serum free Trp to competing amino acids

241

(CAA) ratio was significantly higher (43% p= 0.0000) in the CFS cohort and the serum total Trp to

242

CAA ratio was only significantly higher when co-varied with age and gender (p= 0.0562).39 Non-

243

esterified fatty acid (NEFA) levels were significantly higher in the CFS cohort (p= 0.0192), as was

244

serum glucose (p= 0.0058) and a slightly higher albumin concentration was also seen in the CFS

245

cohort (p= 0.0016).39 Total CAA concentration though was not significantly different between the

246

healthy control cohort and CFS cohort.39 Within CFS participants if suggested serotonin parameters

247

are applied there was a significant division in this cohort between those with high or normal

248

serotonin status shown in free Trp (p= 0.0002) and total Trp to CAA ratio (p= 0.0195) and free Trp

249

to CAA ratio (p= 0.0000).39
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250

Within the second study, the amino acid blood sample findings were related to the research

251

question.40 These findings highlighted baseline free Trp was significantly lower in the CFS cohort

252

(p= 0.033) with no difference seen in neutral amino acid (NAA) concentration between the two

253

groups.40 Although lowered, there was no significant difference between groups for serum free Trp

254

to NAA ratio and there was no difference for total Trp between the groups.40

255

For the amino acid glutamine, the one experimental study revealed baseline measurements of

256

participants with CFS had significantly lower mean plasma (p= <0.001) and muscle (p= 0.027)

257

glutamine concentrations.41 Post trial outcomes for those with CFS in the intervention group

258

receiving a glutamine supplement highlighted there was a significant increase in plasma and muscle

259

glutamine concentration (p= <0.05).41 Those with CFS in the placebo group saw no significant

260

increase in plasma or muscle glutamine concentrations (p= >0.05).41 Although supplementation

261

increased stores of glutamine for CFS participants, those with CFS in the intervention group

262

showed no statistically significant change in their five category questionnaire scores assessing

263

symptoms, whereas CFS participants in the placebo group showed a significant decrease in the two

264

categories of emotionality (p= 0.02) and sleep problems (p= 0.02).41 Grouping CFS participants to

265

show clinical improvement or no clinical improvement displayed both the intervention and control

266

groups in each category.41

267

The CFS participants in the group which showed no clinical improvement did display significant

268

increases in mean plasma glutamine concentration (p= 0.013) post trial as well as increases in their

269

T-cell counts (p= 0.010), T-helper cells (p= 0.002) and a decrease in natural killer cell counts (p=

270

0.019) and activated T-cells (p= 0.015).41 These outcomes oppose the reported baseline measures in

271

the initial assessment, yet were not seen in the group which displayed clinical improvement.

272
273

Phosphate diabetes and consideration of differential diagnosis to CFS

274

Mean serum phosphate concentration was outlined to be significantly lower in the CFS cohort (p=

275

0.01) but still within reference range in the single included analytical observational study.42

276

Fourteen percent of participants in the CFS cohort fulfilled diagnostic criteria for phosphate

277

diabetes (PD), yet did not show a significant difference in symptoms when compared to those with

278

CFS without a PD diagnosis. No statistically significant difference was seen between the

279

intervention and control for mean overall values such as phosphate clearance, mean renal threshold

280

phosphate concentration (TmPO4/GFR) and mean phosphate tubular re-absorption (PTR) rate

281

values.42

282
283

Discussion

284

Within this review no definitive dietary modification was found for alleviation of the symptoms for

285

individuals with CFS. Some promising research though has been examined. The alternative
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286

hypothesis that dietary modifications are useful in alleviating the symptoms of CFS has not been

287

substantiated within this review.

288

The included animal studies set a good platform for further human studies to be conducted in these

289

areas of interest, with some encouraging significant results highlighted through polyphenol use in

290

mice or rats displaying induced fatigue.22-24 Further studies in humans should consider

291

supplementation of these isolated polyphenol compounds, as the results highlighted are unlikely to

292

be obtained through normal dietary intake, for example, to obtain the effects seen from naringin

293

around 50-200 mg/kg was administered.24 Mean values of several fruit varieties high in naringin,

294

including red grapefruit, blond grapefruit and sweetie fruit, showed around 50 mg/100 g of fresh

295

weight from fruit identified, further impeded by it’s bioavailability in the food matrix.43

296

Experimental LSLY dietary intervention was inconclusive. Although, bias from poor compliance

297

must be considered when interpreting these findings, with compliance not analysed against the

298

measured outcome scores. Other reasons for such a finding may be potentially due to lack of power

299

masking a result.4 The results may have been clouded from the beginning as the studies hypothesis

300

relied on dietary treatment of a suggested cause of CFS. Both the suggested cause and use of dietary

301

modification for this suggested cause (LSLY diet) lacked any supporting scientific data, are

302

controversial and to date have not been linked directly to CFS.4

303

Dietary intake patterns and poor vitamin or mineral status were not found to be associated with

304

symptoms alleviation in the observational studies reviewed.25-28 Some important trends were found

305

within these studies. One study notably observed in their selected CFS cohort almost half of the

306

dietary exclusions were made based on information from practitioners of alternative therapy or

307

experience.25 Those following this advice tended to have higher vitamin supplement intake which

308

may be detrimental as discussed by Mursu et al.44, who noted that vitamin and mineral supplements

309

increased total mortality risk in a cohort of generally healthy women with a mean age of 60 years.

310

Although this study displays a low level of evidence and had many limitations25, these trends

311

regarding food avoidance and its influence on the diets of those with CFS are important to note for

312

research and clinical practice in order to ensure the information being distributed and followed

313

within CFS populations is correct and has a sound evidence base. Some supplementation

314

recommendations were highlighted in light of other findings. Due to the nature of CFS with

315

increased in-door dwelling, potential increased osteoporosis risk and significantly lower mean

316

serum 25-OH vitamin D, vitamin D intake through the diet and supplements should be considered

317

for general health, regardless of the study findings26. The risk of chronic vitamin D deficiency

318

mimicking CFS symptoms is also noted in two studies.26, 28 One study continues, suggesting that an

319

underlying pathological process may be responsible for abnormal biomarkers which showed very

320

little correlation with inadequate nutritional intake28, an explanation that may also explain lifestyle

321

factors of weight and dietary intake not significantly correlating with CFS symptoms.27
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322

For the three experimental studies of single nutrient supplements varied results were seen.

323

the study considering probiotic supplementation it was not clear whether participant compliance

324

was measured and this may have influenced the inconsistent results.33 In part, this result may have

325

been seen as this trial might not have used a high enough dose or may have focused on too many

326

different strains of bacteria at once, with Rao et al.45 supporting this hypothesis, highlighting

327

positive outcomes for anxiety and intestinal microflora using a higher single strain probiotic dose.

328

With this understanding of the included probiotic experiment, the potential relationship between the

329

gut-brain axis and probiotic use and the gut microbiota for CFS is further reinforced and needs

330

continued investigation, D-ribose was highlighted to have positive preliminary results although

331

further investigation should be made as the quality rating identified a potential conflict of interest.34

332

Polynutrient vitamin and mineral supplements again displayed inconsistent results across the studies

333

included.30-32 Data from Brouwers et al.30 and Martin et al.32 showed no statistically significant

334

relationship between CFS symptoms and polynutrient supplementation, respectively.30, 32 One of

335

these experimental studies32 did show better non significant scores than those not using the vitamin

336

and mineral supplement. Regardless, these studies do not support general prescription of

337

polynutrient supplements to individuals with CFS. Maric et al.31 highlighted a number of

338

statistically significant results, yet the overall inconsistent results were displayed across the

339

measured outcomes. It was suggested that potentially the vitamin and mineral supplement was

340

working on an inflammatory level, with symptoms related to inflammation significantly improving

341

alongside superoxide dismutase (SOD) activity.31 The change in SOD activity could possibly imply

342

an effect of lowering inflammatory cytokine concentration, overall suggesting decreased levels of

343

oxidative stress could perhaps influence CFS symptoms.31 This suggestion is complemented by

344

Morris et al.46 in sighting that low grade inflammation from heightened pro-inflammatory cytokines

345

are characteristic in those with CFS and that antioxidant use may be helpful. These

346

antioxidant/cytokine hypotheses align with the results seen in the animal models of polyphenols and

347

their positive changes to induced fatigue and corresponding cytokine measured outcomes.22-24

348

Mixed self-applied supplementation gave inconsistent results. Within the included analytical

349

observational study a list of different therapies used over the study duration was cited by noting the

350

most commonly used therapies amongst participants.29 This allows for many other potential

351

treatments to also have been in use concurrently to the listed therapies and dramatically decreases

352

the accuracy of the results.29

353

Studies examining the role of fatty acids and CFS highlighted some positive outcomes, yet overall

354

inconsistent results were seen.36-38 One experimental study returned no significant results, although,

355

the supplements used may have acted as a confounder to these results.38 An EFA supplement

356

containing a range of fatty acids, both n-3 and n-6 PUFA was used although the control supplement

357

did not contain EPA and DHA. Mixing n-3 and n-6 PUFA could have negatively contaminated the

33-35

For
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358

results as highlighted by Maes et al. who made observations regarding plasma free fatty acids.

359

Although, Puri et al.37 did see significant results within their case study from a mixed EFA

360

supplement (predominately n-3 PUFA), the previous hypothesis that n-6 PUFA may negatively

361

impact results should still be taken into consideration for further research work. The positive

362

outcomes seen from supplementation with predominately omega three fatty acids and observations

363

in plasma free fatty acids could indicate the anti-inflammatory role of omega three fatty acids

364

imparting positive effects for inflammatory response in CFS as well as some symptoms reduction.36

365

Findings again were inconsistent for those studies examining the role of tryptophan and glutamine

366

amino acids and CFS.39-41 CFS participants displayed a significantly higher serum free Trp to CAA

367

ratio with increased Trp available to the brain, highlighting an excess of central serotonin by one

368

analytic observational study.39 Although, this was only due to higher serum free Trp as CAA

369

concentration was not different between the two groups. Unfortunately some of the CFS cohort had

370

not fasted and this confounder significantly increased the concentration level of serum free Trp,

371

hence affecting the validity of the serum free Trp to CAA ratio. In light of this result, conflicting

372

findings are understood from another included analytical observational study.40 This data highlights

373

potential implications for the management of CFS, proposing that CFS patients may be divided into

374

sub-groups of those with normal or those with high serotonin status.39 It must be noted that within

375

Vassallo et al.40 observational study, the amino acid level investigation and results observed were

376

reviewed, yet the other sub sectors of this study were not relevant to the research question having

377

largely a neuroendocrine focus.

378

Glutamine amino acids findings showed experimentally that a CFS cohort at baseline displayed

379

significantly lower mean plasma and muscle glutamine concentration, yet it is stated this is likely

380

because of four participants low values.41 Post trial outcomes show those with CFS in the

381

intervention group saw a significant increase in plasma and muscle glutamine concentration as

382

compared to CFS participants in the placebo group who saw no significant increases. This indicates

383

the effectiveness of glutamine supplementation in increasing the bodies supply of the amino acid.

384

Inconsistent results though were highlighted with use of categorisation of CFS participants into

385

clinical improvement or no clinical improvement groupings, with a statistically significant increase

386

for those who did not show clinical improvement post trial in mean plasma glutamine

387

concentration. It is proposed that a rise in only plasma glutamine for this group indicates an issue of

388

glutamine regulation rather than decreased availability of glutamine in those with CFS.

389

Overall it can be stated glutamine supplementation increased body supplies of glutamine but

390

demonstrated inconsistent effects on reported symptoms or clinical improvement.

391

Phosphate diabetes (PD) CFS cohort findings were contradictory and although still within reference

392

range, the CFS group did display a significantly lower mean serum phosphate concentration in the

393

included analytical observational study.42 Fourteen percent of the CFS cohort did meet the PD

38

36
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394

diagnostic criteria, whereas no one in the healthy control group met the diagnostic criteria. Further

395

studies therefore should rule out the need for consideration of PD upon clinical presentation of CFS

396

symptoms to ensure the diagnosis and management are correct.

397

Restricted primary research regarding this topic is a limitation of this review, not only is the data of

398

lower quality and evidence level, the extent of research currently is narrow.5, 13-15 Weaknesses exist

399

within the body of evidence and add to the complexity of this topic. Weaknesses include a variety

400

of differing case definitions and diagnostic criteria for CFS, with the Institute of Medicine

401

redefining CFS highlighting this weakness and aiming to address it.1, 3, 10 Furthermore, a vast

402

number of assessment tools and measures, displaying varying levels of validity are in use for CFS.1,

403

3

404

weaknesses meant that assessment of bias had to be carefully considered. Rather than a uniform

405

assessment of bias be made across the included studies, an overview of individual assessments of

406

limitations, validity and bias was made, provided in Supplementary File 2 available online.

407

Limitations of relatively small sample sizes across much of the included primary research existed,

408

with none of the included studies using an Australian cohort. Further research may benefit from

409

including larger numbers and potentially multi country study designs to ensure greater

410

generalisability to the CFS population.3 As commonly evident in systematic reviews some level of

411

publication bias may be present as only published primary research met the strict inclusion criteria.

412

Not only is there a need for stronger study design and larger sample size use, but also a need for

413

research to assess varying whole diet interventions being applied, as currently from included data in

414

this review only one primary research paper included a specific dietary intervention trial4 with more

415

emphasis in the current body of evidence on supplementation or single nutritive factors.

Relevant insights of study limitations are provided in this review, yet the aforementioned

416
417

Conclusion

418

Overall the evidence displayed inconsistent results across data themes which emerged, with only

419

limited dietary modifications shown to be useful in alleviating symptoms of CFS. The evidence-

420

base included many studies of lower levels of evidence according to the National Health and

421

Medical Research Council18

422

At present, effective dietary changes have not yet been substantiated within this review, including

423

effective communication and implementation of dietary interventions tailored to meet the needs of

424

the CFS population.4 Individualized clinical recommendations still need to focus on evidence-based

425

advice and dietary counselling, alongside general promotion of healthy eating habits across all

426

medically tolerable food groups in order to also reduce other chronic disease risks and avoid

427

development of deficiencies.25, 47

428

Overall further research surrounding the research question and data themes presented in this review

429

is needed. It is hoped that further research will focus on strengthening the level of evidence

13

430

contributing to future research in this area in order to clarify and consolidate recommendations as

431

well as ensure the distribution of accurate and useful information at a population level.

432
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Figure 1 Flow diagram of database searches

Search One: Scopus
Total Records Retrieved: 142
Example Search Strategy: “chronic
fatigue syndrome” OR “CFS” AND
“diet*” AND “supplementation*”

Records screened: 435

Full-text articles assessed for
eligibility: 48

Included

Total number of studies included: 27

Total number of studies included: 22

Search Two: Cinahl Plus
with Full Text
Total Records Retrieved:
243

Search Three: Web of
Science
Total Records Retrieved: 31

Search Four: PsycINFO
Total Records Retrieved:
19

Records excluded: 387

Full-text articles excluded:
21 articles did not meet inclusion criteria components, were not a primary study
or were reviewing disproved treatment strategies i.e. homeopathy (21)

Duplicates removed: 5

Supporting Information: Summary Table of Included Primary Research Papers for:
“Role of Dietary Modification in Alleviating Chronic Fatigue Syndrome Symptoms: A Systematic Review”
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†
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Intervention:
exposure and
duration
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Outcome measures

Population:
sample size.

Results:
effect size and statistical significance/
risk reduction

Confounders

External
validity:
applicability and
generalisability

Quality rating20, #

Animal studies and polyphenols
Kuo et al.
22

(2009)

- Animal study

Not

Four groups

- 6 weeks

- Endurance by forced

- AMF use (100mg/kg body weight)

Not comparable to

Not applicable or

(N/A)

manipulated

(n=8)chronically

- n=40 Sprague

swimming

significantly increased endurance

human evidence, yet

generalisable to

- N/A

(n=8, rats)

fatigued rats

Dawley rats

- Atrophied spleen as

(p<0.05) compared to rats without AMF

provides a platform for

the CFS

through food

measured through

- Spleen/ body weight ratio not

further studies.

population.

intake restrictions

decrease in spleen/body

significantly increased with

and forced

weight ratio

supplementation

swimming. Some

- Spleen cell proliferation

- Spleen cell proliferation significantly

mice received

- Cytokine production

increased with supplementation (p<0.05)

treatment with

- Abnormal cytokine production levels

astragalus

regulated with supplementation (p<0.05)

membranaceus
flavonoids (AMF)
Sachdeva

- Animal study

Not

Three intervention

- 28 days

- Endurance by forced

- EGCG administration significantly

Not comparable to

Not applicable or

et al.

(N/A)

manipulated

groups (n=5-6)

- ~n=22 adult male

swimming

increased endurance capacity and

human evidence, yet

generalisable to

- N/A

(5-6 rats)

One group subject

Wistar rats

23

(2011)

- Cognitive behaviour

decreased fatigue levels (p=<0.05)

provides a platform for

the CFS

to weight loaded

using elevated plus

- Greater endurance and decreased post

further studies.

population.

forced swimming.

maze learning task

fatigue levels displayed with the

Two other groups

- Grip strength using

administration of 100mg/kg (p=<0.05)

also received

rota rod test

- Prevented reductions in body weight

epigallocatechin

- Locomotor activity

and restored spleen and thymus induced

gallate (EGCG)

using atophotometer

hypotrophy (p=<0.05),

polyphenol.

and hyperalgesia

- Significantly greater prevention of body

- Brain homogenate

weight reduction and spleen hypertrophy

oxidative stress,

restoration using100mg/kg (p=<0.05).

nitrosative stress, blood

- Decreased locomotive scores and

tumour necrosis factor-a

increased time for the rota rod and

(TNF-a) glutathione,

hyperalgesia tests (p=<0.05)

superoxide dismutase,

- Elevated plus maze learning task

2
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Study design
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duration

Duration
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Results:
effect size and statistical significance/
risk reduction

Confounders

External
validity:
applicability and
generalisability

Quality rating20, #

catalase activity.

showed decreased initial transfer latency
(p=<0.05)
- Statistically significant changes in
oxidative and nitrosative measures such
as decreases in MDA, nitrite, and serum
TNF-a levels and increased reduced
glutathione, superoxide dismustase and
catalase activity (p=<0.05)
- Further decreases for MDA, nitrite, and
serum TNF-a levels and increases for
reduced glutathione, superoxide
dismustase and catalase activity for the
100mg/kg dose (p=<0.05)

Vij et al.

- Animal study

Injected with

Naringin (natural

- 19 days

- Immobility time

- Significant and dose-dependent

- Not comparable to

Not applicable or

(2009)24

(N/A)

carboxy-

polyphenol)

- ~n=32 Albino Laca

- Mean tail withdrawal

decrease in the duration of immobility

human evidence, yet

generalisable to

- N/A

methyl

administered orally

Mice

latency

(p=<0.05)

does provide a platform

the CFS

cellulose (drug

at differing doses

population.

- Nano moles of MDA

- Significant increase in mean tail

for further studies

transport

- Micro moles of GSH

withdrawal latency (p=<0.05)

- To obtain these effects

substance)

- Nitrite levels

- A significant dose dependant increase

around 50-200mg/kg

and

- Serum tumor necrosis

in reduced glutathione levels (p=<0.05)

naringin was

lipopolysaccha

factor-alpha (TNF-a)

- Oxidative and nitrosative stress

administered. Mean

ride (LPS) or

measures such as MDA measures, brain

values of several fruit

brucella

nitrite levels and serum TNF-a were

varieties high in

abortus (BA)

statistically significantly reduced

naringin showed around

antigen to

(p=<0.05)

50mg/100g of fresh

induce

weight.42 The levels

immunological

tested may not be

fatigue

obtainable through diet
alone.

Dietary interventions and CFS symptom alleviation
Hobday et

- Randomised

Healthy eating

Low sugar, low

- 24 weeks

- Chalder Fatigue Scale

-Intention to treat analysis showed no

- The suggested cause

- Applicable to

3
Reference

Study design
(Level of
†
Evidence )

Control

Intervention:
exposure and
duration

Duration

Outcome measures

Results:
effect size and statistical significance/
risk reduction

- n=52 participants

self report questionnaire

statistically significant difference between

and use of dietary

the CFS

the primary outcome measures.

Population:
sample size.

Confounders

External
validity:
applicability and
generalisability

Quality rating20, #
al. (2008)4

controlled trial

based on

yeast diet (LSLY)

(level II)

British

diagnosed with CFS

for fatigue,

modification for this

population, yet

- Positive

Department of

(9 males and 43

- Quality of life (QoL)

study lack scientific

weighted toward

* ‘experimental

Health

females).

using medical outcomes

evidence and are

the female CFS

study’

Guidelines

survey short form-36

controversial

population

(MOS SF-36).

-Underpowered

- Participants

- Hospital anxiety and

-Poor compliance,

recruited from

depression score

compliant analysis on

within London

(HADS) to assess mood.

baseline characteristics.

where factors
such as sun
exposure are
widely different .

Dietary intake and poor vitamin or mineral status and CFS
Trabal et al.

- Cross-sectional

No control

No intervention

- Study duration N/A

- Food frequency

Patterns of dairy and grain avoidance

- Other disease states

- Applicable only

(2012)25

pilot study (level

group

applied

- n=28 female

questionnaires (FFQ)

were described as most prominent in the

were noted as

to the female

IV)

participants

and three day food

study cohort

confounders, but not

CFS population

- Negative

diagnosed with CFS.

records were collected

adjusted for

- Participants

* ‘descriptive

and analysed for dietary

- Small study sample

were from

observational

habits and food

size

Barcelona,

study’

restrictions

Spain where
access to health
care may vary to
other countries.

Jenkins and

- Case series

No control

Participants with

- n=51 participants

- 4 day diet diary

Low intakes of vitamin D and E, calcium

- Time lapse between

- Predominately

Rayman

(level IV)

group

CFS displaying

with CFS (9 males,

- Routine blood sample

selenium, iodine when compared to UK

initial blood work and

Caucasian,

- Negative

low values for

42 females)

- Participants clinical

reference nutrient intakes.

undertaking of the

making it less

* ‘descriptive

minerals and B

evaluation using Chalder

- Abnormal biomarkers showed very little

dietary assessment

applicability to

observational

vitamins.

Fatigue Scale, the

correlation with inadequate nutritional

- The use of a food

CFS population

General Health

intake.

diary <7 days

as a whole.

Questionnaire (GHQ-

compromised some

Weighted toward

12), HADS, the Work

accuracy and imposed

the females

(2005)

28

study’
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and Social Adjustment

bias to the participant,

- As the

Scale and EQ-5D Health

comparisons

Questionnaire.

were made to
the UK
reference
nutrient intakes
and set in the
setting must be
considered

Goedendor

- Case-control

Dutch

Questionnaire

- No duration is

- A lifestyle

- Significantly less participants in the CFS

- CFS diagnostic criteria

- This study is

p et al.

study (level III-3)

population

data from 247

given for the

questionnaire to

cohort were overweight (18-45 years)

only allows for BMI of

applicable to the

- Neutral

collected by

CFS participants

collection of data

measure smoking and

(p=<0.01), almost one-third CFS cohort

18.5-40 year olds. BMI

CFS population

* ‘descriptive

Statistics

- 247 participants

alcohol use

had an unhealthy BMI

only assessed in n=81

- This study was

observational

Netherlands

with CFS; 70 male,

- Eating habits through

- Through the fat, fruit and vegetable and

of the CFS cohort.

conducted within

177 female

the fat test,

fibre test the CFS cohort showed 95%

- Excess alcohol

a cohort of

- Fuit and vegetable test

had poor fibre intake and unhealthy fat

consumption an

Dutch

and the fibre test

- Fruit, and vegetable intake was

exclusion criteria for

participants

- Body mass index (BMI)

observed in 70% of the CFS cohort

CFS, may also present

- Fatigue severity using

- Lifestyle factors were not significantly

as skewed results

the CIS-fatigue scale

associated with fatigue severity or

- Functional impairment

functional impairment

27

(2009)

study’

using the SIP-8 scale
Berkovitz et

- Retrospective

- A single arm

- Single study arm

- CFS comparison

- Serum 25 OH vitamin

Mean serum 25 OH vitamin D levels

Case notes were used

- The sample

al. (2009)26

survey (level III-3)

study of

consisted of

study arm 2 years of

D levels

were moderately to severely suboptimal

to assess fatigue and

was 95%

- Negative

patients with a

participants with

laboratory data on

- Severity of fatigue

in CFS participant at 60.1% for those not

may not have been

Caucasian,

* ‘descriptive

variety of

CFS

serum 25OH vitamin

assessed from case

taking supplements, statistically

concurrent to when the

making it less

observational

chronic

D and case notes,

notes using the Myalgic

significantly lower over winter/spring

serum 25 OH vitamin D

applicability to

study’

diseases used

n=324 participants. -

Encephalomyelitis

(p=<0.04) and summer/autumn (p=<

sample was taken

the CFS

as control for

CFS comparison

Disability Score (MEDS)

0.003)

population as a

serum 25OHD

study arm n=16

and the Chalder Fatigue

- No relationship between serum 25-OH

whole.

vitamin D

males and n=84

Scale

vitamin D and alleviation of symptoms of

- Weighted

5
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comparison

females

CFS

toward females

(comparable to the

- The setting is

control group).

in Britain where
factors such as
sun exposure
are widely
different

Single nutrient supplements
Witham et

- Randomised

Half of the

100,000 units of

- 6 months

Results pertinent to this review

-

- Not fully

al. (2015)35

controlled trial

study

oral vitamin D3 or

- n=50 participants

-Aarterial stiffness

highlighted no statistically significant

-Funding from ME

applicable to the

(level II)

population

matching mygliol

diagnosed with CFS;

-Fatigue using the Piper

effects in any aspects of the Piper

research UKthough the

CFS population,

- Neutral

acted as a

oil placebo

(12 males and 38

Fatigue Scale –

Fatigue Scale.

funder had no role in

weighted toward

* ‘experimental

control

females).

- Markers of

No statistically significant changes w for

the undertaking the trial

the

study’

receiving a

inflammation and

all metabolic, inflammatory and oxidative

predominately

parallel

oxidative stress

stress outcome measures.

Caucasian,

placebo

interleukin- 6, TNF-a, c-

female adult

reactive protein,

CFS population

derivatives of reactive

-Aa Scottish

oxygen metabolites

cohort and

- Flow-mediated

factors such as

dilatation of the brachial

sun exposure

artery, blood pressure,

are widely

cholesterol and insulin

different

resistance
Sullivan et
33

al. (2009)

- Case series

No control

Probiotic

- 10 weeks (4 weeks

- Symptom intensity

- A statistically significant improvement

- Sstudyparticipants

- The study was

study with pre and

group

supplement

of intervention)

including neurocognitive

for VAS neurocognitive symptoms

acted as their own

applicable to the

post test outcomes

(Cultura Dofilus

- 15 participants with

symptoms using the

(p=0.04)

control, though they did

general CFS

(level IV)

Natural Yoghurt)

CFS; (5 male, 10

Visual Analogue Scales

- No significant change was seen in the

not undertake a placebo

population

females).

(VAS)

SF-12 Health Survey measures

treatment with wash out

-

* ‘experimental

- Physical activity and

- No significant change in aerobic

period

This study was

study’

general health status

intestinal microflora was found

- Neutral

conducted within
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Teitelbaum

- Case series pilot

et al.

study with pre and
34

(2006)

No control

using SF-12 Health

a cohort from

- Stool samples

Sweden

Supplement of 5g

- 17 to 35 days

- Pre and post enrolment

- Statistically significant improvement for

- Gender was

- Proper analysis

D-ribose 3x/day

- n=36 participants

discrete visual analogue

energy levels (p=<0.0001, CI; 1.1-2.2, all

associated in some

was not given to

post test outcomes

diagnosed FMS

scale (DVAS)

other areas spanning 1 for the 95%

areas of the DVAS

CFS patients

(level IV)

and/or CFS (8

questionnaire describing

confidence intervals [CI])

- Study sample

alone to display

- Negative

males,28 females).

energy levels, sleep

- 65.7% experienced some level of

mainlyfemales

a significant

* ‘experimental

patterns, mental clarity,

improvement in regard to their overall

- Two of the three

result.

study’

pain threshold and state

subjective feelings.

researchers worked for

- Participants

of well-being

- Intention to treat analysis was not

the company producing

were from the

- Post enrolment

performed

the D-ribose- may have

Annapolis

subjective feelings

- CFS participants saw improvement in

affected the

region, USA

pre and post DVAS scores for all areas,

interpretation of the

where access to

with no reported p value or 95% CI

results

health care may

- Relatively small study

vary from other

sample size

areas

Polynutrient vitamin and mineral supplements
Maric et al.
31

(2014)

- Case series

No control

Vitamin and

- 2 months

- Before and after

- Statistically significant improvement in

- The small sample size

- Applicable only

study with pre and

group

mineral

- n=38 participants

superoxide dismutase

SOD antioxidant enzyme activity

may have impacted the

to the female

supplement

with CFS (all

(SOD), Fibro Fatigue

(p=<0.005) (decreased oxidative stress

ability to find further

CFS population

(level IV)

female).

Scale (FFS) for

showing decreased SOD)

significant results

- Conducted

- Neutral

.

post test outcomes

symptom severity and

- FFS scores showed improvement in

within a cohort

* ‘experimental

the Quality of Life Short

fatigue (p=0.0009), sleep disorder

from Sweden

study’

Form-36 (QOL SF-36)

(p=0.008), autonomic nervous system

for physical,

symptoms (p=0.018), headaches

psychological and social

(p=0.0001), and subjective feelings

functioning were

surrounding infection (p=0.0002).

completed

- QOL SF-36 showed statistically
significant total physical function
(p=0.053), physical role (p=0.031), pain
(p=0.01) and mental vitality (p=0.029)
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and mental health (p=0.014) function
scores
Martin et al.

- Placebo

Placebo

Vitamin and

- 6 months

General Health

The data analysis showed no statistically

- Nutritional status was

- Applicability to

(1994)32

controlled, double

supplement

mineral

- n=42 participants

Questionnaire (GHQ) for

significant relationship between CFS

not assessed prior to

the CFS

supplement

with CFS

blind, cross over

physical symptoms,

measured outcomes and the vitamin and

the study

population is

study (level II)

Physical Questionnaire

mineral supplement

commencement to

likely to be high

- Neutral

(PQ) scores

establish possible

including

* ‘experimental

nutrient deficiency

participants with

study’

- No clear exclusion

a sum score of

criteria

measuring
outcomes of 12
or over.
Conducted
within a cohort
from Scotland
where factors
such as sun
exposure are
widely different
to other contexts

Brouwers et

- Randomised

Placebo

Polynutrient

- 10 weeks

No statistically significant result was

- Effect on CFS

- The

al. (2002)30

control trial (level

supplement

antioxidant

- n=53 participants

- Fatigue severity using

displayed between the control or

symptoms, nutritional

applicability of

II)

supplement of a

with CFS (16 males,

the Checklist Individual

intervention group in any of the outcomes

status was not

the cohort to the

- Neutral

range of macro

37 females).

Strength (CIS-fatigue)

measured

assessed prior to the

CFS population

* ‘experimental

and micro

score

study commencement

was good yet

study’

nutrients

- Disability through

to establish if possible

weighted toward

Sickness Impact Profile

nutrient deficiency

the female CFS

(SIP-8) score

- The study doesn’t

population

- CDC checklist to

mention whether

- Conducted

assess CFS symptoms.

supplement containers

within a cohort
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:

were returned or if

from the

- Physical activity was

compliance was

Netherlands

measured through

assessed

actometer
- Daily fatigue through
Daily Observed Fatigue
(DOF) rating
- individual self
improvement rating
Mixed self applied supplementation
Bentler et

- Case series

No control

No intervention,

- 2 years

- Fatigue intensity using

- Minimal change in fatigue score - A

Different therapy used

- The study

al. (2005)29

study (level IV)

group

group

- n=159 participants

a mix of the Rand

small number of the total cohort found a

over the study duration

sample was

- Negative

with CFS (20 male,

Vitality Index and the

nutritional therapy useful, of that

Treatments may have

heavily weighted

* ‘analytical

135 female)

Fatigue Severity Scale.

proportion ginseng was found to be most

been in use

toward the

observational

.

- Somatic symptoms

helpful within users (out of 18 subjects,

concurrently to the

female.

through non-validated

56% found this helpful) of the nutritional

listed therapies

Caucasian CFS

questions

supplements considered appropriate for

therefore not

- Depression was

analysis within this review.

highly applicable

assessed using the

- Inconsistent results where information

to the general

Zung Self-Rating

was provided

CFS population.

Depression Scale and

- Magnesium (no specified dose) at 6

- The study was

the MOS SF-36

months was statistically significant with

performed within

improvement in fatigue (p=0.002) -

an American

Calcium (no specified dose) was at 6

cohort

study’

months to 2 years showed statistically
significant improvement in fatigue
(p=0.01), yet was based on 5 participants
Fatty acids and CFS symptom alleviation
Maes et al.
36

(2005)

- Case-control

N=12 normal

N=22 CFS

- No exact duration

- Plasma free fatty acids,

- CFS cohort showed a statistically

- Control participants

- Applicable to

study (level III-2)

control

participants

mentioned; -

serum zinc, serum

significant reduction in the omega three

health status was not

the general CFS

- n=34 participants

alpha-2 protein fraction.

(n-3) to omega six (n-6) polyunsaturated

described

population,

- Neutral
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* ‘analytical

provided blood

CD96 expression on T

fatty acid (PUFA) ratio (p=0.0003) and

- No analysis of dietary

although gender

observational

samples

lymphocytes and T

eicosapentaenoic acid (EPA) to

intake was recorded

was not

helper and suppressor

arachidonic acid (AA) ratio (p=0.02)

quantified

cells

- Statistically significant positive

-

- In the CFS cohort FMS

relationship between n-3:n-6 PUFA ratio

This study was

and CFS Rating Scale to

and serum zinc, an indicator of the

conducted within

measure severity of

inflammatory response (p=0.009)

a cohort from

symptoms

- Statistically significant relationship

Belgium

study’

between lowered n-3 PUFA and the
expression of CD69 on activated T cells
(for CD3+ p=0.005, CD3+CD4+ p=0.04,
CD3+CD8+ p=0.01)
- Statistically significant positive
relationship between the severity of CFS
symptoms and certain n-6 PUFA (LA
p=0.005, AA p=0.038) and n-9 PUFA
(p=0.02), oleic (p=0.03) and palmitic acid
(p=0.02)
- Statistically significant negative
relationship between n-3/n-6 ratio and
severity of CFS symptoms was seen
(p=0.027)
Puri et al.

- Single case

No control

Essential fatty acid

- 16 weeks

- Depression outcome

- Depression scores dropped from 27 at

Only one participant

- Not applicable

(2004)37

study (level IV)

group

supplement rich in

- n=1 female

using the Montgomery

baseline to 3 at 16 weeks.

was included

to the CFS

- Negative

eicosapentaenoic

participant with

and Asberg Depression

- The lateral ventricular volume of the

population as

* ‘case study’

acid (EPA)

diagnosed CFS

Rating Scale.

brain had decreased at 16 weeks

only one

- Lateral ventricular

participant was

brain size was assessed

included

through MRI scan

- This study was
conducted within
a UK participant

10
Reference

Study design
(Level of
†
Evidence )

Control

Intervention:
exposure and
duration

Duration

Outcome measures

Population:
sample size.
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where factors
such as sun
exposure are
widely different
to other contexts
Warren et

- Randomized

Placebo

Essential fatty acid

- 3 months

- Physical Symptom

- No statistically significant differences in

- The EFA supplement

- The study was

al. (1999)38

control trial (level

supplement of

(EFA)

- n=50 participants

(PS) Checklist adapted

the RBC membrane fatty acid profile and

contained a range of

applicable to the

II)

sunflower oil

supplementation

with CFS (21 men,

from another study

symptoms scores from PS and BDI

fatty acids, both n-3 and

general CFS

29 females).

- The Beck Depression

between the intervention and control

n-6 polyunsaturated

population

* ‘experimental

Inventory (BDI) for

group were displayed

fatty acids (PUFA),

- This study was

study’

assessment of

although the control

conducted within

depression

supplement did not

a cohort from

contain EPA and DHA, -

England where

Compliance of

factors such as

participates in the

sun exposure

intervention group is not

are widely

mentioned

different to other

- Neutral

contexts
Tryptophan and glutamine amino acids and CFS
Badawy et

- Case-control

42 healthy

N=23 participants

- 2 year, 7 month

- Serum free and total

- The CFS cohort had significantly higher

- Some of the CFS

- This study is

al. (2005)39

study (level III-2)

participants

with CFS

period

tryptophan (Trp), cortisol

mean free (48%, p=0.0000) and total

cohort were not fasted

applicable to the

- Negative

(26 males, 16

- n=65 participants,

and amino acids,

(19%, p=0.0016) Trp

outcomes indicated

CFS population

* ‘analytical

females)

in the CFS cohort (9

albumin, non-esterified

- Serum free Trp to CAA ratio was

significantly higher

-

observational

males, 14 females).

fatty acids (NEFA),

significantly higher (43%, p=0.0000) in

serum free Trp to CAA

This study was

study’

In the control cohort

glucose and kynurenine,

the CFS cohort

ratio only due to higher

conducted within

all exhibiting some role

- The serum total Trp to CAA ratio was

serum free Trp

a cohort from

in Trp metabolism were

only significantly higher when co-varied

the United

measured

with age and gender (p=0.0562).

Kingdom where

- NEFA levels were significantly higher in

factors such as

the CFS cohort (p=0.0192), as was

sun exposure

serum glucose (p=0.0058) and a slightly

are widely
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higher albumin concentration was also

different to other

seen in the CFS cohort (p= 0.0016).

contexts

- Total CAA concentration though was
not significantly different between the
control and CFS groups

Vassallo et
40

al. (2001)

- Case-control

N=21 healthy

N=20 participants

- A duration not

Relevant to the research

Relevant to the research question were

- One participant who

- This study is

study (level III-2)

participants (5

with CFS(4 males,

mentioned

question - plasma

the amino acid findings:

did not meet the criteria

not applicable to

- Neutral

males, 16

16 female)

- n=41 participants,.

neutral amino acid

- baseline free Trp was significantly lower

for CFS

the CFS

* ‘analytical

female )(

concentration (NAAs)

in the CFS cohort (p=0.033)

population as

observational

- plasma total and free

- no difference was seen in NAA

one participant

study’

Trp was measured

concentration between the two groups

in the CFS

- from these measures

- although lowered there was no

cohort did not

the ratio of free Trp to

significant difference between groups for

meet the criteria

NAA was given

serum free Trp to NAA ratio

for CFS
diagnosis
This study was
conducted within
a cohort from
the United
Kingdom where
factors such as
sun exposure
are widely
different to other
contexts

Rowbottom

- Randomised

Placebo

L-glutamine

- 26 weeks

- Glutamine status of

- CFS group reported more frequently the

Relatively small study

The study

et al.

double blind case-

supplement

supplement

- n=32 participants;

control and intervention

occurrence of symptoms for all five

sample size

population in this

(1998)41

controlled trial

(2000mg/day for

groups

categories of the questionnaire

trial is applicable

(level II)

trial duration)

- Un-fasted blood

(p=<0.001)

to the CFS
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- Neutral

16 participants

sample for plasma

- The CFS group showed significantly

population and

* ‘experimental

with CFS (6

glutamine levels,

lower mean T-cell counts (p=0.002), T-

generalisability

study’

males, 10

complete haematology,

helper cell counts (p=0.018) and higher

is dependant on

females)

five cell differential

activated T-cells (p=0.027)

the context

leucocyte counts and

- The CFS participants displayed

cortisol and testosterone

significantly lower mean plasma

analysis.

(p=<0.001) and muscle (p=0.027)

- Muscle glutamine

glutamine concentrations pre trial

concentration

- CFS participants in the intervention

- 5 category

group showed no statistically significant

questionnaire regarding

change in their five category

symptom status

questionnaire scores, whereas CFS
participants in the placebo group showed
a significant decrease in the two
categories of emotionality (p=0.02) and
sleep problems (p=0.02)
- For those in the intervention group with
CFS a significant increase in plasma and
muscle glutamine concentration was
seen (p=<0.05). - CFS participants who
did not show clinical improvement
showed significant increases in mean
plasma glutamine concentration
(p=0.013) post trial andsignificant
increases in T-cell counts (p=0.010), Thelper cells (p=0.002) and a decrease in
natural killer cell counts (p=0.019) and
activated T-cells (p=0.015).
- CFS participants with or without clinical
improvements post trial displayed
significant increases in erythrocyte
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counts, haemoglobin, haematocrit
(p=<0.05) and a significant decrease in
B-cells (p=<0.05)
Phosphate diabetes and consideration of differential diagnosis to CFS
De Lorenzo

- Case-control

N=37 healthy

N=87 participants

- No duration

- Urinary sodium,

- Mean serum phosphate concentration

Analysis of PD was

- This study is

et al.

study (level III-2)

control

with CFSod

mentioned; -

potassium, calcium and

was significantly lower in the CFS cohort

performed among the

applicable to the

- Neutral

participants

samples

42

(1998)

- Participants

phosphate, b serum

(p=0.01) but within reference range

cohort – no analysis of

CFS population

* ‘analytical

provided blood and

calcium and phosphate,

- 14% of participants in the CFS cohort

dietary intake to reduce

-

observational

urine samples

parathyroid hormone

fulfilled diagnostic criteria for phosphate

the impact that poor

Tonsidered as

study’

- n=124 participants

and vitamin D were

diabetes (PD), yet dno significant

dietary intake

this study was

(51 males, 46

measured

difference in symptoms

females)

- Phosphate clearance,

conducted within
a cohort from

phosphate tubular re-

- no statistically significant difference for

London where

absorption (PTR) and

overall mean values, such as phosphate

factors such as

renal threshold

clearance, mean TmPO4/GFR and mean

sun exposure

phosphate concentration

PTR rate values

are widely

(TmPO4/GFR) were all

different to other

measured

contexts



†



The evidence level of each included study was graded according to the National Health and Medical Research Council.19

A quality rating was assigned according to the Academy of Nutrition and Dietetics American Dietetic Association20 quality rating checklist allowing assessment of risk of bias within each included study and fostering
systematic and objective quality ratings assignment. The checklist addresses relevance, applicability, validity and bias.



Study title descriptor given to the references when described within the systematic literature review itself to allow the reader quick reference and comparison of study designs
FMS: fibromyalgia, CFS: chronic fatigue synrome

